BHU scientists ink MoU with MNC | india | Hindustan Times
  • Wednesday, Jul 18, 2018
  •   °C  
Today in New Delhi, India
Jul 18, 2018-Wednesday
-°C
New Delhi
  • Humidity
    -
  • Wind
    -

BHU scientists ink MoU with MNC

SCIENTISTS OF the Institute of Technology, Banaras Hindu University signed a Memorandum of Understanding with Alkem Laboratories Limited, a multi-national firm, in Mumbai on Tuesday, as part of their efforts to promote industry-institute partnership.

india Updated: Jan 05, 2006 00:11 IST

SCIENTISTS OF the Institute of Technology, Banaras Hindu University signed a Memorandum of Understanding with Alkem Laboratories Limited, a multi-national firm, in Mumbai on Tuesday, as part of their efforts to promote industry-institute partnership.

A three-member team of IT-BHU, including IT director Prof SN Upadhyay, chief co-ordinator of Industry Institute Partnership (IIP) Cell Dr Pradeep Kumar Mishra and IIP Cell co-ordinator Dr Pradeep Kumar Srivastava signed the MoU with Alkem Laboratories Limited chairman Sampada Singh.

“Alkem Laboratories has signed the MoU to fulfil provisions of the World Trade Organisation and Intellectual Property Rights,” Dr Pradeep Kumar Mishra of the Chemical Engineering Department at IT told HT from Mumbai on telephone.
Dr Mishra said this move would also help in strengthening industry-institute partnership, which would provide practical exposure to students.

He further said they had already developed a low-molecular weight heparin (to act as an anti-coagulant injection) for Alkem Laboratories.

He claimed that it was for the first time that these injections were developed in India. “Earlier, these injections were made in Italy and the United States of America,” he said. The injections developed by them would be available in the market by the end of 2006 at a cheaper price than foreign ones, he added.

Dr Mishra said these injections were needed to avoid blood clotting, which occurred due to cerebral stroke, brain injury, road accidents and sometimes in cases of heart attack. “These injections play a significant role in the treatment of deep venous thrombosis,” he said.

Anti-coagulant injections were passed by the National Chemical Laboratory (Pune) and clinical tests in these injections were currently under way.